Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for ImmunoTech (AIM) over the last 10 years, with Q1 2025 value amounting to $60000.0.

  • ImmunoTech's Share-based Compensation fell 2500.0% to $60000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $256000.0, marking a year-over-year decrease of 5345.45%. This contributed to the annual value of $686000.0 for FY2024, which is 18230.45% up from last year.
  • As of Q1 2025, ImmunoTech's Share-based Compensation stood at $60000.0, which was down 2500.0% from $196000.0 recorded in Q4 2024.
  • Over the past 5 years, ImmunoTech's Share-based Compensation peaked at $329000.0 during Q3 2024, and registered a low of $50000.0 during Q2 2023.
  • For the 3-year period, ImmunoTech's Share-based Compensation averaged around $109777.8, with its median value being $80000.0 (2024).
  • Per our database at Business Quant, ImmunoTech's Share-based Compensation soared by 55800.0% in 2024 and then tumbled by 2500.0% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Share-based Compensation stood at $61000.0 in 2023, then skyrocketed by 221.31% to $196000.0 in 2024, then tumbled by 69.39% to $60000.0 in 2025.
  • Its Share-based Compensation stands at $60000.0 for Q1 2025, versus $196000.0 for Q4 2024 and $329000.0 for Q3 2024.